AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

1-192 (Canceled).

193. (Currently amended) ~~An anti-cancer pharmaceutical combination~~ A composition[[,]] comprising:

(a) ~~a composition comprising an amount of~~ a complement-activating antibody that binds to a cancer cell, and at least one pharmaceutically acceptable carrier; and

(b) an orally administered composition comprising a 1,3-β glucan derived from barley ~~having a molecular weight of from about 120,000 Da to about 450,000 Da,~~ in an amount effective to enhance the antibody's anti-tumor effect, and at least one pharmaceutically acceptable carrier;

wherein the antibody binds to a cancer cell expressing an antigen selected from the group consisting of CD20, HER2, EGFR, GD2, and GD3.

194. (Currently amended) The composition ~~pharmaceutical combination~~ of claim 193 wherein compositions (a) and (b) are administered to the subject concurrently or sequentially.

195. (Currently amended) The composition ~~pharmaceutical combination~~ of claim 193, wherein the antibody is a monoclonal antibody.

196. (Currently amended) The composition ~~pharmaceutical combination~~ of claim 193, wherein the antibody is further

capable of activating an antibody dependent cell-mediated cytotoxicity response.

197. (Currently amended) The composition ~~pharmaceutical combination~~ of claim 193, wherein the antibody is directed to a cancer cell expressing the antigen EGFR.

198. (Currently amended) The composition ~~pharmaceutical combination~~ of claim 193, wherein the antibody is directed to a cancer cell expressing the antigen GD2.

199. (Currently amended) The composition ~~pharmaceutical combination~~ of claim 193, wherein the antibody is directed to a cancer cell expressing the antigen GD3.

200. (Currently amended) The composition ~~pharmaceutical combination~~ of claim 193, wherein the antibody is directed to a cancer cell expressing the antigen CD20.

201. (Currently amended) The composition ~~pharmaceutical combination~~ of claim 193, wherein the antibody is directed to a cancer cell expressing the antigen HER2.

202. (Currently amended) The composition ~~pharmaceutical combination~~ of claim 193, wherein the cancer cell expressing CD20 is non-Hodgkin's lymphoma, Hodgkin's lymphoma, or Epstein-Barr related lymphoma.

203. (Currently amended) The composition ~~pharmaceutical combination~~ of claim 202, wherein the lymphoma is non-Hodgkin's lymphoma.

204. (Currently amended) The composition ~~pharmaceutical combination~~ of claim 197, wherein the cancer cell expressing the EGFR is an epidermoid cancer cell.

205. (Currently amended) The composition ~~pharmaceutical combination~~ of claim 198, wherein the cancer cell expressing the antigen GD2 is a neuroblastoma.

206. (Currently amended) The composition ~~pharmaceutical combination~~ of claim 199, wherein the cancer cell expressing the antigen GD3 is a melanoma cancer cell.

207. (Currently amended) The composition ~~pharmaceutical combination~~ of claim 201, wherein the cancer cell expressing the antigen HER2 is a breast cancer cell.

208-211. (Canceled)

212. (Currently amended) The composition ~~pharmaceutical combination~~ of claim 193, wherein the amount of the orally administered 1,3-β glucan is about >= 25 mg/kg/day, five days a week for a total of 2-4 weeks.

213-218. (Canceled)

219. (Currently amended) ~~An anti-cancer pharmaceutical combination, comprising,~~ A composition comprising:

(a) ~~a composition comprising an amount of~~ a complement-activating antibody that binds to a cancer cell, and at least one pharmaceutically acceptable carrier; an

(b) an orally administered composition comprising a 1,3-β glucan derived from barley ~~having a molecular weight of from about 120,000 Da to about 450,000 Da,~~ in an amount

effective to enhance the antibody's anti-tumor effect, and at least one pharmaceutically acceptable carrier;

wherein the cancer cell is selected from the group consisting of neuroblastoma, melanoma, non-Hodgkin's lymphoma, breast cancer, Epstein-Barr related lymphoma, Hodgkin's lymphoma, and epidermoid carcinoma.

220. (Currently amended) The composition ~~pharmaceutical combination~~ of claim 219, wherein compositions (a) and (b) are administered to the subject concurrently or sequentially.

221. (Currently amended) The composition ~~pharmaceutical combination~~ of claim 219, wherein the antibody is a monoclonal antibody.

222. (Currently amended) The composition ~~pharmaceutical combination~~ of claim 219, wherein the antibody is further capable of activating an antibody dependent cell-mediated cytotoxicity response.

223. (Currently amended) The composition ~~pharmaceutical combination~~ of claim 219, wherein the antibody is directed to EGFR (epidermal growth factor receptor).

224. (Currently amended) The composition ~~pharmaceutical combination~~ of claim 219, wherein the antibody is directed to antigen GD2.

225. (Currently amended) The composition ~~pharmaceutical combination~~ of claim 219, wherein the antibody is directed to antigen GD3.

226. (Currently amended) The composition ~~pharmaceutical combination~~ of claim 219, wherein the antibody binds to the antigen CD20.

227. (Currently amended) The composition ~~pharmaceutical combination~~ of claim 219, wherein the antibody binds to the antigen HER2.

228-231. (Canceled)

232. (Currently amended) The composition ~~pharmaceutical combination~~ of claim 219, wherein the amount of the orally administered β glucan is about >= 25 mg/kg/day, five days a week for a total of 2-4 weeks.

233-238. (Canceled)